{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T18:13:58Z","timestamp":1773080038986,"version":"3.50.1"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,11]]},"DOI":"10.7759\/cureus.96605","type":"journal-article","created":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T22:52:23Z","timestamp":1762901543000},"source":"Crossref","is-referenced-by-count":2,"title":["Concurrent Nemolizumab-Induced Cutaneous Adverse Events and Asthma Exacerbation in a Patient With Prurigo Nodularis With Resolution of Both Conditions After Switching to Dupilumab"],"prefix":"10.7759","author":[{"given":"Yoshihito","family":"Mima","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masako","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken","family":"Iozumi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.04.182","article-title":"Prurigo nodularis: pathogenesis and management","volume":"83","author":"Williams KA","year":"2020","unstructured":"Williams KA, Huang AH, Belzberg M, Kwatra SG. Prurigo nodularis: pathogenesis and management. J Am Acad Dermatol. 2020, 83:1567-75. 10.1016\/j.jaad.2020.04.182","journal-title":"J Am Acad Dermatol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2024.06.1276","article-title":"Pathophysiology of prurigo nodularis: neuroimmune dysregulation and the role of type 2 inflammation","volume":"145","author":"Kwatra SG","year":"2025","unstructured":"Kwatra SG, St\u00e4nder S, Yosipovitch G, Kim BS, Levit NA, O'Malley JT. Pathophysiology of prurigo nodularis: neuroimmune dysregulation and the role of type 2 inflammation. J Invest Dermatol. 2025, 145:249-56. 10.1016\/j.jid.2024.06.1276","journal-title":"J Invest Dermatol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02320-9","article-title":"Dupilumab in patients with prurigo nodularis: two randomized, double-blind, placebo-controlled phase 3 trials","volume":"29","author":"Yosipovitch G","year":"2023","unstructured":"Yosipovitch G, Mollanazar N, St\u00e4nder S, et al.. Dupilumab in patients with prurigo nodularis: two randomized, double-blind, placebo-controlled phase 3 trials. Nat Med. 2023, 29:1180-90. 10.1038\/s41591-023-02320-9","journal-title":"Nat Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2301333","article-title":"Phase 3 trial of nemolizumab in patients with prurigo nodularis","volume":"389","author":"Kwatra SG","year":"2023","unstructured":"Kwatra SG, Yosipovitch G, Legat FJ, et al.. Phase 3 trial of nemolizumab in patients with prurigo nodularis. N Engl J Med. 2023, 389:1579-89. 10.1056\/NEJMoa2301333","journal-title":"N Engl J Med"},{"key":"ref5","unstructured":"Novel drug approvals for 2024. (2024). Accessed. November 11, 2025: https:\/\/www.fda.gov\/drugs\/novel-drug-approvals-fda\/novel-drug-approvals-2024."},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14093026","article-title":"Cutaneous adverse events following nemolizumab administration: a review","volume":"14","author":"Mima Y","year":"2025","unstructured":"Mima Y, Yamamoto M, Iozumi K. Cutaneous adverse events following nemolizumab administration: a review. J Clin Med. 2025, 14:3026. 10.3390\/jcm14093026","journal-title":"J Clin Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.81349","article-title":"A case of cutaneous fungal infection following the administration of dupilumab","volume":"17","author":"Tanemura S","year":"2025","unstructured":"Tanemura S, Mima Y. A case of cutaneous fungal infection following the administration of dupilumab. Cureus. 2025, 17:e81349. 10.7759\/cureus.81349","journal-title":"Cureus"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.79070","article-title":"A case of erythema multiforme following the administration of nemolizumab","volume":"17","author":"Mima Y","year":"2025","unstructured":"Mima Y, Ohtsuka T. A case of erythema multiforme following the administration of nemolizumab. Cureus. 2025, 17:e79070. 10.7759\/cureus.79070","journal-title":"Cureus"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2003.09.008","article-title":"Development of the asthma control test: a survey for assessing asthma control","volume":"113","author":"Nathan RA","year":"2004","unstructured":"Nathan RA, Sorkness CA, Kosinski M, et al.. Development of the asthma control test: a survey for assessing asthma control. J Allergy Clin Immunol. 2004, 113:59-65. 10.1016\/j.jaci.2003.09.008","journal-title":"J Allergy Clin Immunol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1038\/ni1084","article-title":"Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice","volume":"5","author":"Dillon SR","year":"2004","unstructured":"Dillon SR, Sprecher C, Hammond A, et al.. Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice. Nat Immunol. 2004, 5:752-60. 10.1038\/ni1084","journal-title":"Nat Immunol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0902769","article-title":"IL-31 receptor (IL-31RA) knockout mice exhibit elevated responsiveness to oncostatin M","volume":"185","author":"Bilsborough J","year":"2010","unstructured":"Bilsborough J, Mudri S, Chadwick E, Harder B, Dillon SR. IL-31 receptor (IL-31RA) knockout mice exhibit elevated responsiveness to oncostatin M. J Immunol. 2010, 185:6023-30. 10.4049\/jimmunol.0902769","journal-title":"J Immunol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1917006","article-title":"Trial of nemolizumab and topical agents for atopic dermatitis with pruritus","volume":"383","author":"Kabashima K","year":"2020","unstructured":"Kabashima K, Matsumura T, Komazaki H, Kawashima M. Trial of nemolizumab and topical agents for atopic dermatitis with pruritus. N Engl J Med. 2020, 383:141-50. 10.1056\/NEJMoa1917006","journal-title":"N Engl J Med"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1007\/s00251-002-0520-2","article-title":"Variations in the human Th2-specific chemokine TARC gene","volume":"54","author":"Sekiya T","year":"2003","unstructured":"Sekiya T, Tsunemi Y, Miyamasu M, et al.. Variations in the human Th2-specific chemokine TARC gene. Immunogenetics. 2003, 54:742-5. 10.1007\/s00251-002-0520-2","journal-title":"Immunogenetics"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1177\/17103568251380242","article-title":"Transient elevation of eosinophil and thymus and activation-regulated chemokine levels associated with cutaneous adverse events due to Nemolizumab: a case report [PREPRINT]","volume":"0","author":"Mima Y","year":"2025","unstructured":"Mima Y, Yamamoto M, Iozumi K. Transient elevation of eosinophil and thymus and activation-regulated chemokine levels associated with cutaneous adverse events due to Nemolizumab: a case report [PREPRINT]. Dermatitis. 2025, 0:0. 10.1177\/17103568251380242","journal-title":"Dermatitis"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.2340\/actadv.v105.44310","article-title":"The absence of recent systemic therapy can be a significant risk factor for nemolizumab-associated cutaneous adverse events in patients with prurigo nodularis: a single-centre retrospective study","volume":"105","author":"Mima Y","year":"2025","unstructured":"Mima Y, Yamamoto M, Iozumi K. The absence of recent systemic therapy can be a significant risk factor for nemolizumab-associated cutaneous adverse events in patients with prurigo nodularis: a single-centre retrospective study. Acta Derm Venereol. 2025, 105:adv44310. 10.2340\/actadv.v105.44310","journal-title":"Acta Derm Venereol"},{"key":"ref16","doi-asserted-by":"crossref","DOI":"10.1242\/bio.036244","article-title":"Correction: IL-31 plays dual roles in lung inflammation in an OVA-induced murine asthma model","volume":"8","author":"Huang J","year":"2019","unstructured":"Huang J, Yue H, Jiang T, et al.. Correction: IL-31 plays dual roles in lung inflammation in an OVA-induced murine asthma model. Biol Open. 2019, 8:bio036244.","journal-title":"Biol Open"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1804092","article-title":"Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma","volume":"378","author":"Castro M","year":"2018","unstructured":"Castro M, Corren J, Pavord ID, et al.. Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. N Engl J Med. 2018, 378:2486-96. 10.1056\/NEJMoa1804092","journal-title":"N Engl J Med"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2025.03.026","article-title":"A case of concurrent exacerbation of manifestations and asthma after the initiation of nemolizumab treatment for atopic dermatitis","volume":"61","author":"Katsuta M","year":"2025","unstructured":"Katsuta M, Osawa A, Ishiuji Y, Fujii S, Kanbe M, Asahina A, Nobeyama Y. A case of concurrent exacerbation of manifestations and asthma after the initiation of nemolizumab treatment for atopic dermatitis. JAAD Case Rep. 2025, 61:89-91. 10.1016\/j.jdcr.2025.03.026","journal-title":"JAAD Case Rep"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/433136-concurrent-nemolizumab-induced-cutaneous-adverse-events-and-asthma-exacerbation-in-a-patient-with-prurigo-nodularis-with-resolution-of-both-conditions-after-switching-to-dupilumab","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T22:52:24Z","timestamp":1762901544000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/433136-concurrent-nemolizumab-induced-cutaneous-adverse-events-and-asthma-exacerbation-in-a-patient-with-prurigo-nodularis-with-resolution-of-both-conditions-after-switching-to-dupilumab"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,11]]},"references-count":18,"URL":"https:\/\/doi.org\/10.7759\/cureus.96605","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11,11]]}}}